In addition, the compound bardoxolone, a synthetic Nrf2 activator, decreased glomerulosclerosis, interstitial fibrosis, inflammation, and NF-κB activation in experimental models of kidney disease [32,33,34]. The gene discussed is NFE2L2; the disease is kidney disorder.